Research And Development
Health
Pharmaceutical

Array BioPharma

$26.27
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.85 (3.33%) Today
-$0.13 (-0.49%) After Hours

Why Robinhood?

You can buy or sell ARRY and other stocks, options, ETFs, and crypto commission-free!

About

Array BioPharma, Inc. engages in the research, development, and commercialization of targeted small molecule drugs for the treatment of cancer and other high-burden diseases. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. Read More The company was founded by Kevin Koch, Anthony Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO.

Employees
298
Headquarters
Boulder, Colorado
Founded
1998
Market Cap
5.66B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
2.80M
High Today
$26.51
Low Today
$25.20
Open Price
$25.70
Volume
3.07M
52 Week High
$26.82
52 Week Low
$12.56

Collections

Research And Development
Health
Pharmaceutical
Cancer Prevention
Biotechnology
Technology

News

BenzingaMay 16

Why Array BioPharma Shares Fell Thursday

Pharmaceutical company Array BioPharma Inc. (NASDAQ: ARRY) shares dipped more than 3 percent Thursday following comments from a sell-side analyst that investors may have to wait longer for results from Array's BeaconCRC colon cancer study. The results were expected to be presented at the American Society of Clinical Oncology meeting later this month, but the late-breaking abstract no longer appears on the conference's program, a Bloomberg reporter tweeted Thursdasy. Michelle Fay Cortez said the abstract w...

864
Seeking AlphaMay 7

Array BioPharma Inc. (ARRY) CEO Ron Squarer on Q3 2019 Results - Earnings Call Transcript

Array BioPharma Inc. (NASDAQ:ARRY) Q3 2019 Earnings Conference Call May 7, 2019 9:00 AM ET Company Participants Andrea Flynn - Senior Director of Investor Relations & Corporate Communications Ron Squarer - Chief Executive Officer Andy Robbins - Chief Operating Officer Jason Haddock - Chief Financial Officer Conference Call Participants Chris Shibutani - Cowen Anupam Rama - JPMorgan Stephen Willey - Stifel Peter Lawson - SunTrust Michael Schmidt - Guggenheim Jim Birchenough - Wells Fargo Eun Yan...

274
Markets InsiderMay 7

EARNINGS SUMMARY: Details of Array BioPharma Inc. Q3 Earnings Report

(RTTNews) - Below are the earnings highlights for Array BioPharma Inc. (ARRY): -Earnings: -$37.49 million in Q3 vs. -$22.85 million in the same period last year. -EPS: -$0.17 in Q3 vs. -$0.11 in the same period last year. -Analysts projected -$0.20 per share -Revenue: $64.68 million in Q3 vs. $66.37 million in the same period last year....

182

Earnings

-$0.25
-$0.18
-$0.12
-$0.05
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
Actual
Expected Aug 13, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.